Related Experiment Video
Updated: Feb 13, 2026

Production of Monoclonal Antibodies Targeting Aminopeptidase N in the Porcine Intestinal Mucosal Epithelium
Published on: May 18, 2021
Targeted therapies in solid tumors: monoclonal antibodies and small molecules
Louis M Weiner1, Hossein Borghaei
1Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA. Louis.Weiner@fccc.edu
Abstract:
The considerable progress in our understanding of the complex cellular, molecular, and genetic mechanisms underlying tumorigenesis over the last decade has fostered the development of novel and improved targeted therapies in cancer intervention. Because these therapies specifically interfere with signaling pathways essential for tumor cell proliferation, survival, and migration, they may be able to inhibit tumor growth and metastasis effectively, with fewer severe adverse events than seen with current chemotherapeutic interventions that have a narrow therapeutic index and are associated with severe toxic side effects. Monoclonal antibodies and protein tyrosine kinase inhibitors represent two classes among these promising new therapeutic interventions. This review discusses the advantages, limitations, and potential of monoclonal antibodies and protein tyrosine kinase inhibitors, and offers a perspective on the requirements and goals likely to propel the design of additional anticancer agents in the future.
Insights
Novel targeted cancer therapies, including monoclonal antibodies and protein tyrosine kinase inhibitors, show promise for inhibiting tumor growth and metastasis with fewer side effects than traditional chemotherapy.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Significant advancements in understanding tumorigenesis mechanisms.
- Development of targeted therapies offers improved cancer intervention strategies.
- Targeted therapies aim to inhibit tumor cell proliferation, survival, and migration.
Purpose of the Study:
- Review novel targeted cancer therapies.
- Discuss monoclonal antibodies and protein tyrosine kinase inhibitors.
- Provide perspective on future anticancer agent design.
Main Methods:
- Literature review of targeted cancer therapies.
- Analysis of monoclonal antibodies and protein tyrosine kinase inhibitors.
- Discussion of therapeutic advantages and limitations.
Main Results:
- Targeted therapies demonstrate potential for effective tumor growth and metastasis inhibition.
- These therapies may offer a better safety profile compared to conventional chemotherapy.
- Monoclonal antibodies and protein tyrosine kinase inhibitors are key examples.
Conclusions:
- Targeted therapies represent a promising frontier in cancer treatment.
- Further research is needed to optimize existing agents and develop new ones.
- Understanding molecular mechanisms is crucial for future anticancer drug design.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Molecular and Ionic Solids
Molecular Solids
Molecular crystalline solids, such as ice, sucrose (table sugar), and iodine, are solids that are composed of neutral molecules as their constituent units. These molecules are held together by weak intermolecular forces such as London dispersion forces, dipole-dipole interactions, or hydrogen bonds, which...
Metallic Solids
All metallic solids exhibit high thermal and electrical conductivity, metallic luster, and malleability....
Structures of Solids
Molecular Comparison of Gases, Liquids, and Solids
Network Covalent Solids
To break or to melt a covalent network solid, covalent bonds must be broken. Because covalent bonds are relatively strong, covalent network solids are typically...

